Clinical Trial Unit

We provide a central platform for the professional conduct of observational and interventional therapeutic clinical studies at the DZNE Munich.

Our work focuses on the investigation of etiologically defined neurodegenerative diseases:

  • Autosomal dominant Alzheimer's disease (Amyloid-beta pathology)
  • Early onset Alzheimer's disease (genetic amyloid beta risk constellations)
  • Frontotemporal dementia (FTD; genetic risk constellations in TARDBP, GRN, C9orf72, FUS, MAPT)
  • Progressive Supranuclear Paresis, Corticobasal Degeneration (PSP / CBD; 4R-Tau Pathology)
  • Parkinson's disease, including with GBA mutations (neuronal synuclein pathology)
  • Multisystem Atrophy (MSA; glial synuclein pathology)
  • Vascular-related neurodegeneration (monogenic vascular diseases; vascular cognitive impairment, vascular Parkinsonism)

Tasks

  • Key tasks
    • Ermöglichung interventioneller Therapie-Studien
    • Biobanking nach DZNE Biobank-Regularien (DNA, Serum, Fibroblasten, …)
    • Entwicklung weiterer DZNE Projekte entsprechend den Regularien der klinischen Forschung am DZNE
  • Tasks in cooperation
    • Molecular diagnostics (genetics, biomarkers[e. g. progranulin], PET[Amyloid, Tau])
    • Imaging diagnostics (MRI, PET[FDG], SPECT[FP-CIT, IBZM])

Contact

Sabine Gallagher (Office)
sabine.gallagher@dzne.de
+49 89 440046-464
+49 89 440046-565

Adress

Klinische DZNE Studieneinheit
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Feodor-Lynen Str. 17
D-81377 München

Info-Hotline

Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Inform yourself on our website cookie-free. However, we would be pleased if you would allow us to use statistical cookies. Your browser settings regarding cookies are currently as follows:
More information can be found in our Privacy policy.